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Summary
Background:  Studies  assessing  ﬁbrin  sealants  use  during  total  knee  replacement  (TKR)  have
produced inconsistent  results.  We  evaluated  ﬁbrin  sealant  therapy  in  TKR  procedures  performed
without tourniquet  and  without  postoperative  drains.
Hypothesis:  Use  of  a  ﬁbrin  sealant  during  TKR  decreases  calculated  total  blood  loss,  thereby
diminishing  blood  transfusion  requirements  and  costs.
Patients  and  methods:  We  studied  62  patients  with  primary  knee  osteoarthritis  who  underwent
TKR by  the  same  surgeon  between  September  2009  and  December  2010.  Fibrin  sealant  was  used
only in  the  last  31  patients,  who  were  compared  to  the  ﬁrst  31  patients  regarding  calculated
total blood  loss,  blood  transfusion  rate,  and  mean  number  of  red-blood-cell  units  used  per
patient. Costs  were  compared  in  the  two  groups.
Results:  In  the  control  group,  mean  total  blood  loss  calculated  using  the  method  of  Gross  was
1.3 ±  0.6  L,  48%  of  patients  required  blood  transfusions,  and  the  mean  number  of  units  per
patient was  0.9  ±  1.  In  the  ﬁbrin-sealant  group,  29%  of  patients  required  blood  transfusions
and the  mean  number  of  units  was  0.6  ±  0.9.  The  between-group  differences  in  favour  of  the
ﬁbrin-sealant  group  were  not  statistically  signiﬁcant.  In  each  group,  compared  with  patients
not requiring  blood  transfusions,  patients  needing  transfusions  had  signiﬁcantly  lower  starting
preoperative  haemoglobin  values  and  a  signiﬁcantly  greater  positive  difference  between  the
calculated  total  blood  loss  and  the  maximum  allowable  blood  loss.  In  the  test  group,  the  cost
of the  31  units  of  ﬁbrin  sealant  was  9743  D and  the  cost  reduction  due  to  using  11  fewer  red-
blood-cell units  was  only  3484  D.  Hospital  stay  was  not  signiﬁcantly  shorter  in  any  of  the  two
groups.
Discussion:  Blood  transfusion  minimisation  during  TKR  should  rely  chieﬂy  on  correcting  pre-
operative  anaemia  and  optimizing  transfusion  decisions  based  on  the  difference  between  the
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total  blood  loss  and  the  maximum  allowable  blood  loss.  Fibrin  sealant  did  not  signiﬁcantly
diminish transfusion  requirements  in  our  study.  Randomised  studies  in  larger  patient  populations
are needed.  The  cost  of  ﬁbrin  sealant  may  exceed  the  expected  cost  savings  in  relation  with
decreased  blood  transfusion  requirements.
Level  of  evidence:  Level  III  (before-after  therapeutic  study).
© 2012  Elsevier  Masson  SAS.  All  rights  reserved.
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bIntroduction
Blood  loss  minimisation  during  orthopaedic  surgical  proce-
dures  is  a  major  concern  given  the  limited  availability  of
blood  products  and  the  risks  associated  with  both  blood
transfusion  and  postoperative  anaemia  [1].  Strategies  sug-
gested  to  date  include  intra-  and  postoperative  cell  salvage,
tranexamic  acid  therapy  and  autologous  blood  transfu-
sion.  However,  there  are  numerous  contraindications  to
tranexamic  acid  [2,3], and  autologous  blood  transfusion  is
declining  in  popularity  because  of  its  cumbersome  nature,
particularly  in  elderly  patients.  Fibrin  sealants  were  devel-
oped  long  ago  and  found  effective  in  several  orthopaedic
procedures  on  the  hip,  knee,  and  spine  [4—9].
Total  knee  replacement  (TKR)  is  associated  with  signiﬁ-
cant  blood  loss.  Thus,  total  blood  loss  (TBL)  ranges  from  1.2
to  1.8  L  or  more.  Substantial  bleeding  occurs  via  the  drains
during  the  ﬁrst  few  postoperative  days  [2,3,9—13],  and  24
to  58%  of  patients  require  blood  transfusions  [8—10,14—16].
The  application  of  ﬁbrin  sealant  during  TKR  has  been
reported  to  decrease  bloody  drainage  during  the  postoper-
ative  period  [8,9], thereby  diminishing  the  total  amount  of
blood  lost  [9].  However,  effects  on  the  blood  transfusion  rate
have  varied  across  studies.  Thus,  the  blood  transfusion  rate
decrease  seen  with  ﬁbrin  sealant  was  signiﬁcant  in  a  study
by  Levy  et  al.  [9]  but  non-signiﬁcant  in  a  study  by  Wang  et  al.
[8].
Here,  we  report  a  preliminary  prospective  non-
randomised  study  in  62  consecutive  patients  undergoing
TKR.  Fibrin  sealant  was  used  only  in  the  last  31  patients.  To
minimize  postoperative  blood  loss,  we  made  two  changes  to
our  usual  surgical  protocol  at  the  beginning  of  the  study:
we  performed  step-by-step  haemostasis  instead  of  using
a  tourniquet,  with  the  result  that  bleeding  at  the  end
of  the  procedure  was  sufﬁciently  limited  to  obviate  the
need  for  drains.  The  study  intervention  consisted  in  spray-
ing  ﬁbrin  sealant  over  the  entire  surgical  ﬁeld  in  the  last
31  patients.  Our  working  hypothesis  was  that  ﬁbrin-sealant
therapy  would  further  decrease  the  calculated  TBL,  thereby
diminishing  blood  transfusion  requirements.  We  prospec-
tively  monitored  and  compared  the  control  group  and  the
test  group  in  order  to  evaluate  our  working  hypothesis.  We
also  compared  costs  in  the  two  groups.
Patients and methods
We  included  62  patients  who  underwent  unilateral  TKR  by
the  same  surgeon  (PM)  at  our  institution  between  September
2009  and  December  2010.  The  reason  for  TKR  was  advanced
primary  knee  osteoarthritis  in  all  patients.  None  of  the
patients  had  coagulation  disorders.
s
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iThe ﬁrst  31  patients  had  surgery  between  September
009  and  February  2010,  without  ﬁbrin  sealant.  In  the  last
1  patients,  who  had  surgery  between  February  and  Decem-
er  2010,  a  single  change  was  made  to  the  surgical  protocol,
amely  the  addition  of  a  ﬁbrin-sealant  spray.  Table  1  reports
he  main  patient  characteristics.  No  signiﬁcant  differences
ere  found  between  the  control  and  ﬁbrin-sealant  groups
or  age,  sex,  body  mass  index  (BMI),  or  American  Society
f  Anesthesiologists  (ASA)  score.  The  mean  preoperative
aemoglobin  concentration  was  signiﬁcantly  higher  in  the
brin-sealant  group.
We  used  ﬁbrin  sealant  derived  only  from  human  plasma
Quixil®,  Ethicon,  Johnson  &  Johnson,  Depuy  France,  Issy-
es-Moulineaux,  France).  This  product  replicates  the  ﬁnal
teps  of  the  clotting  cascade.  Each  5  ml  dose  contains  a  con-
entrate  of  human  clottable  proteins,  a  solution  of  puriﬁed
uman  thrombin,  and  calcium  chloride.
The  same  surgical  procedure  was  used  in  all  62  patients.
he  cementless  prosthesis  for  primary  TKR  Natural  Knee® II
Zimmer,  Warsaw,  IN,  USA)  was  implanted  via  the  subvastus
edialis  approach,  without  patellar  resurfacing.  Computer-
ssisted  navigation  was  used  in  all  patients,  obviating  the
eed  for  an  intramedullary  guidewire.  No  tourniquet  was
sed,  and  step-by-step  haemostatic  electrocoagulation  was
erformed.  The  Quixil® administration  device  was  used  to
dminister  the  5  ml  ﬁbrin-sealant  dose  (Fig.  1).  The  throm-
in  and  clottable-protein  mix  are  packaged  in  two  separate
ials  connected  via  two  separate  ports  to  a  syringe  that
as  a  single  plunger  and  nozzle,  so  that  both  solutions  are
rawn  simultaneously  and  mixed  in  the  syringe.  We  con-
ected  the  syringe  to  a  pressure  regulator  to  achieve  a
niform  spray  by  depressing  the  plunger.  The  nozzle  was  held
bout  15  cm  from  the  tissues,  which  were  as  dry  as  possible,
o  ensure  coverage  with  a  superﬁcial  ﬁlm  of  ﬁbrin  sealant.
ibrin  sealant  was  ﬁrst  applied  to  the  posterior  part  of  the
oint  before  implantation  of  the  prosthetic  components.  The
emaining  sealant  was  applied  on  the  anterior  aspect  of  the
urgical  ﬁeld,  after  prosthesis  implantation  and  just  before
ound  closure.  No  drains  were  left  in  place.  A  compression
andage  was  used  for  the  ﬁrst  8  h.
Prophylactic  low-molecular-weight  heparin  therapy  was
iven  for  1  month.  Sitting  was  started  on  the  ﬁrst  postop-
rative  day  and  standing  with  weight  bearing  on  the  next
ay.  A  continuous  passive  motion  machine  was  used  starting
n  the  ﬁrst  postoperative  day,  with  a  femoral  nerve  block
chieved  via  a  portable  elastomeric  pump  loaded  with  ropi-
acaine  solution.  The  femoral  nerve  block  was  replaced  by
ubcutaneous  opioid  analgesics  after  48  h  and  subsequently
y  step-1  analgesics  based  on  the  visual-analogue-scale  pain
core.  Patients  were  discharged  to  rehabilitation  centres
 to  10  days  after  surgery  depending  on  bed  availabil-
ty.
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Table  1  Comparison  of  the  demographic  data  and  results  in  the  groups  with  and  without  ﬁbrin-sealant  therapy  (Quixil®).
Without  Quixil® With  Quixil® P  value  Power  (%)
n =  31  n  =  31
Age 72  ±  8  69  ±  10  <  0.2
M/F ratio  0.29  0.55  <  0.2
Blood volume  in  L 4.4  ±  0.8  4.6  ±  0.5  <  0.2
Preoperative  Hb  in  g/dL 13  ±  1.2 14  ±  1 <  0.04*
ASA  1/2/3 11/16/4 12/18/1 <  0.3
Blood loss  in  L  (Gross) 1.34  ±  0.57 1.44  ±  0.63 <  0.3 10
Blood loss  in  L  (Mercuriali) 0.60  ±  0.44 0.55  ±  0.38 <  0.8 7.70
Blood transfusion  rate  0.48  0.29  <  0.1  33.30
Mean number  of  RBC  units/patient  0.9  ±  1.1  0.6  ±  0.9  <  0.2  21.70
M: male; F: female; Hb: haemoglobin; ASA: American Society of Anesthesiologists; L: litre; dL: decilitre; RBC: red-blood-cell.
* Statistically signiﬁcant difference.
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the  real  calculated  blood  loss  [21,22].
To  identify  factors  associated  with  the  blood  transfu-
sion  rate,  we  evaluated  the  inﬂuence  in  each  group  of  age,
ASA  score,  preoperative  haemoglobin  concentration,  TBL,
Table  2  Blood  transfusion  protocol  used  in  both  study
groups.
Haemoglobin  level
7  to  9  g/dL Transfusion  except  if
Age  <  60  years
AND  ASA  1
AND  good  clinical  tolerance
Age  >  75  years
9 to  10  g/dL  No  transfusion  except  if
AND/OR  history  of  cardiovascular
diseaseigure  1  Ready-to-use  kit  for  applying  the  ﬁbrin  sealant
Quixil®).
The  study  was  conducted  prospectively.  A  speciﬁc  blood
ransfusion  protocol  was  followed.  No  blood  transfusions
ere  given  during  surgery.  Homologous  blood  transfusions
ere  used  as  needed  during  the  postoperative  period,
fter  the  patients  had  returned  to  the  surgical  ward.  The
aemoglobin  concentration  was  determined  on  the  ﬁrst  and
hird  postoperative  days  and  at  discharge.  Prescribing  rec-
mmendations  were  based  on  the  1988  National  Institutes  of
ealth  consensus  conference  indicating  8  g/dL  as  the  lowest
cceptable  haemoglobin  concentration  with  a  haematocrit
o  lower  than  27%  in  women  and  30%  in  men  [17]. As  shown
n  Table  2,  the  protocol  was  adjusted  according  to  spe-
iﬁc  patient  characteristics  (age,  cardiovascular  history,  ASA
core,  and  clinical  tolerance  of  the  anaemia).  Blood  transfu-
ions  were  given  on  the  third  and  fourth  postoperative  days.
he  haemoglobin  concentration  was  determined  2  days  after
he  last  blood  transfusion.
The  main  evaluation  criterion  was  calculated  TBL.  The
econdary  evaluation  criteria  were  the  blood  transfusion
ate  and  the  mean  number  of  red-blood-cell  (RBC)  units
er  patient.  TBL  was  computed  based  on  the  haemoglobin
oncentration  drop  according  to  Gross  [18]  and  on  the  Mer-
uriali  and  Inghilleri  formula  [19]  taking  into  account  both
on-compensated  blood  loss  and  compensated  blood  loss,
ith  each  homologous  RBC  unit  being  considered  equivalentigure  2  Formulas  of  Gross  and  of  Mercuriali  and  Inghilerri
or estimating  total  blood  loss.
o  150  mL  of  blood  volume  (Fig.  2).  These  two  meth-
ds  produce  noticeably  different  results,  since  the  method
escribed  by  Gross  uses  the  mean  of  the  preoperative  and
f  the  lowest  postoperative  haematocrit  values.  With  both
ethods,  the  haemoglobin  drop  is  weighted  for  blood  vol-
me  estimated  using  Nadler’s  formula  [20]. As  no  drains
ere  used,  postoperative  exteriorized  bleeding  was  not
easured.  However,  postoperative  or  apparent  bleeding  was
hown  an  unreliable  parameter  because  it  does  not  reﬂectAND/OR  ASA  2  or  3
AND/OR  poor  clinical  tolerance
ASA: American Society of Anesthesiologists.
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Figure  3  Distribution  of  the  number  of  red-blood-cell  (RBC)
units in  the  groups  with  and  without  ﬁbrin-sealant  therapy.
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and  the  difference  between  the  maximum  allowable  blood
loss  (MABL)  and  the  TBL  according  to  Helm  et  al.  [15]  (in
theory,  a  negative  difference  indicates  a  need  for  blood
transfusion).  We  retrospectively  assessed  compliance  with
the  blood  transfusion  protocol  by  determining  the  number  of
patients  transfused  despite  a  positive  MABL/TBL  difference
and  the  number  not  transfused  despite  a  negative  MABL/TBL
difference  in  each  group.
The  cost  of  ﬁbrin-sealant  therapy  was  computed  as  the
difference  between  the  cost  of  the  ﬁbrin  sealant  used  and
the  cost  savings  related  to  the  blood-transfusion-sparing
effect  of  ﬁbrin-sealant  therapy.  Blood  transfusion  costs
include  the  time  spent  by  nurses  to  check  compatibility  and
to  administer  the  transfusion  and  the  cost  of  storing  and
transporting  the  RBC  units  (546.12  British  pounds  for  two
units  in  a  2006  study  by  Agrawal  et  al.  [23], i.e.,  316  D
per  unit  at  the  current  exchange  rate).  At  present,  a  5  ml
Quixil® dose  costs  314.32  D.  Costs  may  also  be  inﬂuenced
by  other  factors  such  as  a  possible  decrease  in  hospital  stay
length  related  to  a  blood  transfusion-sparing  effect  of  ﬁbrin-
sealant  therapy.  In  our  study,  mean  hospital  stay  length  was
10  ±  2  days  in  the  transfused  group  and  9  ±  3  days  in  the  non-
transfused  (NS)  group.  However,  we  did  not  speciﬁcally  study
this  parameter,  as  it  was  biased  by  discharge  delays  due  to
limited  bed  availability  in  rehabilitation  centres.
For  the  statistical  analysis,  we  used  Student’s  t  test  to
compare  quantitative  variables  (e.g.,  TBL,  age  and  BMI),  or
the  Mann-Whitney  test  for  groups  of  fewer  than  25  patients;
and  the  chi2 test  for  qualitative  variables  and  proportions
(e.g.,  blood  transfusion  rate,  sex  distribution,  and  ASA  score
distribution),  with  Yates’  correction  for  small  sample  sizes  if
appropriate.  Values  of  P  smaller  than  0.05  were  considered
signiﬁcant.  Statistical  power  for  detecting  differences  in  TBL
values  and  transfusion  rates  was  assessed  based  on  sample
size  and  standard  deviations.
Results
In  the  control  group  (no  ﬁbrin  sealant),  calculated  TBL
was  0.60  ±  0.43  L,  according  to  Mercuriali  and  Inghilleri  and
1.34  ±  0.57  L,  according  to  Gross.  The  transfusion  rate  was
48%  and  the  mean  number  of  units  per  patient  was  0.9  ±  1
(Table  1  and  Fig.  3).
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Table  3  Comparison  of  transfused  and  non-transfused  patients  w
Transfusion
n =  9
Age 73  ±  7  
M/F ratio  0.50  
Blood volume  (l) 4.5  ±  0.4  
ASA 1/2/3 2/7/0
Preoperative  Hb  in  g/dL 12.7  ±  1.0  
TBL  in  L  (Gross)  1.7  ±  0.8  
TBL- MABL  (mL)  479  ±  776  
M: male; F: female; Hb: haemoglobin; ASA: American Society of Anesthe
TBL: total blood loss; MABL: maximum allowable blood loss.
* Statistically signiﬁcant difference.ibrin-sealant  therapy  was  associated  with  the  use  of  11  fewer
BC units.
Calculated  TBL  obtained  using  the  method  of  Gross  or
hat  of  Mercuriali  and  Inghilleri  was  not  signiﬁcantly  dif-
erent  in  the  ﬁbrin-sealant  group  compared  to  the  control
roup.  The  ﬁbrin-sealant  group  had  a lower  transfusion  rate
29%  versus  48%)  and  a  smaller  number  of  units  per  patient
0.6  ±  0.9  versus  0.9  ±  1.1)  but  neither  difference  was  sta-
istically  signiﬁcant  (Table  1).  No  blood  transfusion-related
omplications  were  recorded.  The  only  adverse  event  was
terile  wound  discharge  requiring  wound  revision  in  one
atient  in  the  ﬁbrin-sealant  group.
Within-group  comparisons  of  transfused  and  NS  patients
howed  no  signiﬁcant  differences  for  age,  ASA  score,
stimated  blood  volume,  or  TBL.  In  contrast,  highly  signiﬁ-
ant  differences  were  found  for  preoperative  haemoglobin
oncentration  and  the  MABL/TBL  difference  (Tables  3  and  4).
e  retrospectively  identiﬁed  10  deviations  to  our  protocol.
n  six  patients  (three  in  each  group),  our  protocol  indicated
 need  for  blood  transfusion  based  on  a  haemoglobin  level
etween  9  and  10  g/dL  with  age  older  than  75  years  and  an
SA  score  of  2  or  3,  but  these  patients  were  not  transfused.
n  ﬁve  of  these  six  patients,  TBL  was  larger  than  MABL.  In
our  patients  (two  in  each  group),  blood  transfusion  was
ithin  the  group  given  ﬁbrin-sealant  therapy  (Quixil®).
No  transfusion
n  =  22  P  value
67  ±  11  <  0.3
0.57  <  0.5
4.6  ±  0.6  <  0.42
10/11/1  <  0.1
14.1  ±  1.2  <  0.01*
1.3  ±  0.5  <  0.13
−158  ±  492  <  0.02*
siologists; Hb: haemoglobin concentration; L: litre; mL: millilitre;
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Table  4  Comparison  of  transfused  and  non-transfused  patients  within  the  group  not  given  ﬁbrin-sealant  therapy.
Transfusion  No  transfusion  p  value
n =  15  n  =  16
Age  75  ±  9  71  ±  8  <  0.12
M/F ratio  0.15  0.45  <  0.3
Blood volume  (l)  4.2  ±  0.7  4.6  ±  0.8  <  0.22
ASA 1/2/3  4/8/03  7/8/01  <  0.3
Preoperative  Hb  in  g/dL 12.3  ±  1.2  13.7  ±  0.8  <  0.005*
TBL  in  L  (Gross)  1.3  ±  0.6  1.3  ±  0.6  <  0.82
TBL-MABL (mL) 327  ±  398 −129  ±  505  <  0.002*
M: male; F: female; Hb: haemoglobin; ASA: American Society of Anesthesiologists; Hb: haemoglobin concentration; L: litre; mL:  millilitre;
TBL: total blood loss; MABL: maximum allowable blood loss.
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t* Statistically signiﬁcant difference.
rdered  despite  haemoglobin  concentrations  greater  than
0  g/dL  because  of  a  history  of  severe  cardiovascular  dis-
ase.  In  three  of  these  four  patients,  TBL  remained  smaller
han  MABL.
The  cost  of  the  31  doses  of  ﬁbrin  sealant  was  9743  D,
hich  was  more  than  the  cost  savings  of  3484  D related  to
he  use  of  11  fewer  RBC  units.
iscussion
sing  a  ﬁbrin  sealant  did  not  signiﬁcantly  decrease  blood  loss
n  our  study.  In  contrast,  Levy  et  al.  [9]  found  a  signiﬁcant
ecline  in  calculated  TBL  from  1.7  to  1  L  in  a  population
imilar  to  ours.  A  tourniquet  and  postoperative  drains  were
sed  in  the  studies  by  Levy  et  al.  [9]  and  Wang  et  al.  [8].
oth  studies  showed  a  decrease  in  bloody  drainage,  which
ay  therefore  constitute  the  main  effect  of  ﬁbrin-sealant
herapy.
Our  ﬁbrin-sealant  group  had  a  lower  blood  transfusion
ate  and  a  smaller  mean  number  of  RBC  units  per  patient
ompared  to  the  control  group,  but  neither  difference  was
tatistically  signiﬁcant.  In  a  population  of  similar  size,  Levy
t  al.  found  a  signiﬁcant  drop  in  the  transfusion  rate  from  55
o  20%  in  the  ﬁbrin-sealant  group  [9].  However,  they  did  not
eport  preoperative  haemoglobin  values,  which  may  have
ntroduced  a  substantial  bias.  Wang  et  al.  [8]  reported  a
on-signiﬁcant  decrease  in  the  transfusion  rate  from  50%
ithout  Quixil® to  36%  with  Quixil® in  groups  of  respec-
ively  25  and  28  patients,  which  is  consistent  with  our  results
ut  seems  to  contradict  the  signiﬁcant  decrease  in  bleed-
ng  in  the  earlier  study  [8].  However,  when  we  compared
ransfused  and  NS  patients,  we  found  that  the  most  pow-
rful  predictor  of  blood  transfusion  was  the  preoperative
aemoglobin  concentration  and  not  TBL,  in  keeping  with
esults  by  Cushner  et  al.  [24]. The  importance  of  the  pre-
perative  haemoglobin  concentration  is  further  supported
y  two  studies  [1,22]  in  which  this  parameter  strongly  pre-
icted  the  risk  of  postoperative  complications  in  patients
ith  a  history  of  cardiovascular  disease.  Therefore,  the  cor-
ection  of  preoperative  anaemia  deserves  careful  attention.
urthermore,  we  found  that  the  difference  between  MABL
nd  TBL  was  strongly  associated  with  the  risk  of  requiring
lood  transfusion,  in  agreement  with  a  study  by  Helm  et  al.
r
r
s15]. We  identiﬁed  ten  deviations  from  our  blood-transfusion
rotocol:  six  patients  were  not  transfused  despite  meeting
lood-transfusion  criteria  and  four  were  transfused  despite
ot  meeting  blood-transfusion  criteria.  As  the  frequency  of
rotocol  deviations  was  similar  in  the  two  groups,  these
eviations  probably  had  no  impact  on  the  between-group
omparisons.  However,  taking  the  difference  between  MABL
nd  TBL  into  account  would  have  decreased  the  number  of
eviant  indications  to  one  in  each  group.
Our  cost  analysis  indicated  that,  in  our  hands,  ﬁbrin-
ealant  therapy  increased  the  total  cost  of  TKR.  A  blood
ransfusion  rate  decrease  of  22%  would  have  been  statis-
ically  signiﬁcant  and  would  have  spared  the  use  of  16  RBC
nits,  thereby  decreasing  costs  by  4000  D,  which  would  have
een  less  than  half  the  cost  of  the  ﬁbrin  sealant  (9743  D).
ang  et  al.  [8]  reported  that  using  25  Quixil® doses  (7858  D)
pared  13  RBC  units  (4108  D)  and  Levy  et  al.  [9]  that  using
t  least  29  Quixil® doses  (9115.28  D)  spared  19  RBC  units
6004  D).  In  the  study  by  Levy  et  al.  [9],  in  some  cases  two
 mL  kits  were  required  per  patient,  which  increased  the
ost.  An  analysis  of  these  two  studies  [8,9]  done  by  Steuten
t  al.  [25]  showed  that  using  5  mL  Quixil® doses  induced  cost
avings  when  absence  of  blood  transfusions  was  associated
ith  shorter  hospital  stays,  which  was  not  the  case  in  our
tudy.
Our  study  has  several  limitations.  We  used  a  non-
andomised  design.  However,  performance  bias  was  min-
mised,  as  all  procedures  were  done  by  the  same  surgeon,
 noticeable  difference  with  the  two  randomised  studies  of
brin-sealant  therapy  in  TKR.  Second,  the  statistical  power
f  the  comparison  was  diminished  by  the  marked  variabil-
ty  in  blood  loss,  to  only  10%  (i.e.,  there  was  a  90%  risk  of
nding  no  difference  although  a difference  exists).  To  obtain
0%  power,  300  patients  would  have  been  required  in  each
roup.  Power  was  33%  for  ﬁnding  a  signiﬁcant  difference  in
he  blood  transfusion  rate.  Finally,  the  higher  preoperative
aemoglobin  concentration  in  the  Quixil® group  would  have
een  expected  to  decrease  the  blood  transfusion  rate  in  this
roup.  However,  despite  this  source  of  bias  in  favour  of  the
est  group,  no  signiﬁcant  difference  in  the  blood  transfusion
ate  was  found  between  the  two  groups.
In  conclusion,  blood  loss  minimisation  is  challenging
egardless  of  the  surgical  technique  used.  Conceivably,
tudies  in  larger  populations  of  patients  having  similar
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preoperative  haemoglobin  concentrations  might  ﬁnd  evi-
dence  that  ﬁbrin  sealants  are  effective.  However,  blood  loss
minimisation  during  TKR  should  rely  chieﬂy  on  correction  of
preoperative  anaemia  and  on  the  use  of  blood  transfusion
protocols  with  adjustments  not  only  for  age  and  the  ASA
score,  but  also  for  MABL.  The  present  cost  of  ﬁbrin  sealants
seems  to  preclude  a  cost-saving  effect  related  to  decreased
use  of  blood  products.
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